OncoMune Scientists Announce Breakthrough Proof Of Concept Finding At International Immunology Symposium

OncoMune announced today that Chief Scientific Officer Anahit Ghochikyan, Ph.D. presented data which demonstrates unequivocally for the first time the ability of a cancer vaccine to induce tumor regression by targeting a novel class of proteins called "epigenetic regulators of transcription." The vaccine, OCM-111™, represents a unique approach to cancer therapy which causes the eradication of tumor cells while preventing their mutation to escape the vaccine's effect.